Ruiling Zu

Dr. Ruiling Zu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2025 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
HLHuaichao Luo
Huaichao Luo
CWChangchun Wu
Changchun Wu
SYSisi Yu
Sisi Yu
HRHanxiao Ren
Hanxiao Ren
XYXing Yin
Xing Yin
DWDongsheng Wang
Dongsheng Wang
Platelets are vital in many pathophysiological processes, yet there is a lack of a comprehensive resource dedicated specifically to platelet research. To fill this gap, we have developed PlateletBase, a knowledge base aimed at enhancing the understanding and study of platelets and related diseases. Our team retrieved information from various public databases, specifically extracting and analyzing RNA sequencing (RNA-seq) data from 3711 samples across 41 different conditions available on the National Center for Biotechnology Information (NCBI). PlateletBase offers six analytical and visualization tools, enabling users to perform gene similarity analysis, pair correlation, multi-correlation, expression ranking, clinical information association, and gene annotation for platelets. The current version of PlateletBase includes 10,278 genomic entries, 31,758 transcriptomic entries, 4869 proteomic entries, 2614 omics knowledge entries, 1833 drugs, 97 platelet resources, 438 diseases/traits, and six analysis modules. Each entry has been carefully curated and supported by experimental evidence. Additionally, PlateletBase features a user-friendly interface designed for efficient querying, manipulation, browsing, visualization, and analysis of detailed platelet protein and gene information. The case studies on gray platelet syndrome and angina pectoris demonstrate that PlateletBase is a suitable tool for identifying diagnostic biomarkers and exploring disease mechanisms, thereby advancing research in platelet functionality. PlateletBase is accessible at http://plateletbase.clinlabomics.org.cn/.

1 October 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
RZRuiling Zu
Ruiling Zu
SYSisi Yu
Sisi Yu
GYGuishu Yang
Guishu Yang
YGYiman Ge
Yiman Ge
DWDongsheng Wang
Dongsheng Wang
HLHuaichao Luo
Huaichao Luo

11 April 2023 in Platelets
Verified
Journal Article
Open access
SLShan Liu
Shan Liu
GYGuishu Yang
Guishu Yang
GZGuangqun Zeng
Guangqun Zeng
XZXihao Zhou
Xihao Zhou
RCRong Chen
Rong Chen
HLHuaichao Luo
Huaichao Luo
Tumor-educated platelets (TEPs) have been widely reported to have promising application potential; nonetheless, platelet isolation from peripheral blood is an important but neglected step in TEPs research for platelet-based liquid biopsy. In this article, we discussed some common influence factors for platelet isolation. To investigate the factors involved in platelet isolation, a prospective multicenter study was conducted on healthy Han Chinese adults (18 to 79 years of age). A total of 208 individuals were included in the final statistical analysis out of the 226 healthy volunteers who were prospectively enrolled from four hospitals. The primary study metric was the platelet recovery rate (PRR). The similar pattern was observed in the four hospitals, The PRR at room temperature (23°C±2°C) was slightly higher than the PRR at cold temperature (4°C±2°C). Moreover, the PRR gradually decreased as the storage time increased. The PRR for samples within 2 hours of storage is significantly higher than for samples beyond 2 hours (p < .05). Additionally, PRR was also affected by the equipment used in different centers. This study confirmed several factors that influence platelet isolation. In our study, we indicated that platelet isolation should be performed within two hours of peripheral blood draw and held at room temperature until isolation, and that centrifuge models should be fixed during the extraction process, which will further improve the research progress of platelet-based liquid biopsy in cancer. What is the context? What is new? What is the impact?

8 July 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SNSujiao Ni
Sujiao Ni
PXPingyao Xu
Pingyao Xu
KZKaijiong Zhang
Kaijiong Zhang
HZHaiming Zou
Haiming Zou
HLHuaichao Luo
Huaichao Luo
RZRuiling Zu
Ruiling Zu
Gram-negative bacteremia (GNB) is a common complication in malignant patients. Identifying risk factors and developing a prognostic model for GNB might improve the survival rate. In this observational and real-world study, we retrospectively analyzed the risk factors and outcomes of GNB in malignant patients. Multivariable regression was used to identify risk factors for the incidence of GNB, while Cox regression analysis was performed to identify significant prognostic factors. A prognostic model was constructed based on Cox regression analysis and presented on a nomogram. ROC curves, calibration plots, and Kaplan–Meier analysis were used to estimate the model. It comprised 1004 malignant patients with Bloodstream infection (BSI) in the study cohort, 65.7% (N = 660) acquired GNB. Multivariate analysis showed gynecologic cancer, hepatobiliary cancer, and genitourinary cancer were independent risk factors related to the incidence of GNB. Cox regression analysis raised that shock, admission to ICU before infection, pulmonary infection, higher lymphocyte counts, and lower platelet counts were independent risk factors for overall survival (OS). The OS was significantly different between the two groups classified by optimal cut-off value (log-rank, p < 0.001). Above all, a nomogram was created based on the prognostic model, which was presented on a website freely. This real-world study was concentrated on the malignant patients with GNB and proved that shock, admission to ICU before infection, pulmonary infection, higher lymphocyte counts, and lower platelet counts were related to the death of these patients. And a prognostic model was constructed to estimate the risk score of mortality, further to reduce the risk of death.

20 December 2025 in Cell Biology and Toxicology
Verified
Journal Article
Open access
PDF file
RWRuohao Wu
Ruohao Wu
YLYuping Li
Yuping Li
XLXin Li
Xin Li
RZRuiling Zu
Ruiling Zu
PZPeiyin Zhang
Peiyin Zhang
HLHuaichao Luo
Huaichao Luo
The role of platelets in blood coagulation and vascular repair is well known. In recent years, extensive attention has been given to the fact that the impact of tumors on peripheral blood platelets plays a key role in cancer progression. This review systematically summarizes the latest research progress on how tumors regulate the quantity, volume, composition, and activation status of peripheral blood platelets through multiple mechanisms. First, tumor cells can induce excessive platelet production by activating AhR-RUNX1 signaling through paracrine pathways and the release of kynurenine, thereby leading to thrombocytosis, which is associated with advanced tumor stages, metastasis, and poor prognosis. Second, tumor progression may trigger disseminated intravascular coagulation (DIC) or chemotherapy-related bone marrow suppression, which in turn results in consumptive thrombocytopenia. In addition, dynamic changes in the mean platelet volume (MPV) are related to tumor type and progression stage, which may reflect abnormal megakaryocyte differentiation or inflammatory status. In terms of platelet composition, tumor cells can remodel the proteome and transcriptome of platelets by secreting ADP, IgG, and functional RNA. Changes in RNA profiles have been confirmed to have potential for tumor diagnosis. In terms of activation status, tumor cells can induce platelet activation and aggregation (TCIPA) by releasing procoagulant factors such as tissue factors and exosomes (EVs), accelerating thrombosis and promoting angiogenesis. In clinical applications, platelet-related biomarkers have become a research hotspot for early cancer diagnosis and prognostic evaluation. Moreover, targeting platelets affected by tumors provides new strategies for tumor treatment. On the basis of the scientific findings of numerous existing studies, it is speculated that there seems to be a "dynamic balance" among platelets, which also provides a new direction for future research.

28 October 2025 in Cancer Research
Verified
Journal Article
Open access
HLHuaichao Luo
Huaichao Luo
WGWei Guo
Wei Guo
XLXinyu Luan
Xinyu Luan
TYTao Yue
Tao Yue
SYSisi Yu
Sisi Yu
SCShifu Chen
Shifu Chen
Indeterminate pulmonary nodules (IPN) are increasingly detected due to increasing health awareness and widespread lung cancer screening, yet distinguishing benign from malignant nodules remains a critical challenge. Emerging evidence suggests that recognizing cancer-associated immune signatures represents a powerful approach for early-stage cancer detection. This study explored the clinical utility of T-cell receptor (TCR) repertoire analysis in IPN evaluation. By conducting large-scale TCR sequencing (6,059 blood and 988 tumor samples), we established LungTCR (https://www.lungtcr.com/), a comprehensive TCR repertoire database, and proposed a method for the quantitative assessment of tumor-related immune responses. LungTCR was leveraged to develop TCRnodseek plus, a diagnostic model integrating clinical data, CT imaging, and TCR features. A multicenter prospective study (ChiCTR2200055761) involving 1,107 patients with IPN validated the superior diagnostic performance of TCRnodseek plus over existing approaches. Mechanistic analyses revealed that the identified lung cancer–related TCR clones are enriched in non–small cell lung cancer and are predominantly present in malignant nodules and tumor tissues. This study provides a robust TCR database and an advanced diagnostic model, offering a framework for precise IPN differentiation. Significance: Construction of the largest TCR database of lung nodules enabled identification of lung cancer–specific TCR sequences and development of an advanced machine learning model to distinguish benign from malignant pulmonary nodules. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .